Related Experiment Videos

A modifier of Huntington's disease onset at the MLH1 locus

Jong-Min Lee1,2,3, Michael J Chao1,2, Denise Harold4

  • 1Molecular Neurogenetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA 02114, USA.

Human Molecular Genetics
|September 22, 2017
PubMed

Insights

Genetic factors influence Huntington's disease (HD) onset. A variant near MLH1 delays motor symptoms by 0.7 years per allele, offering a potential therapeutic target for this neurodegenerative disease.

Area of Science:

  • Neurogenetics
  • Genomics
  • Molecular Biology

Background:

  • Huntington's disease (HD) is a neurodegenerative disorder inherited dominantly, primarily caused by expanded CAG repeats in the HTT gene.
  • While CAG repeat size is a major determinant of HD clinical features like motor onset age, other genetic factors are increasingly recognized as modifiers.
  • Previous genome-wide association studies identified potential modifier loci on chromosomes 8, 15, and 3.

Purpose of the Study:

  • To validate and identify genetic modifiers influencing the age of motor onset in Huntington's disease.
  • To pinpoint specific functional variants and genes responsible for modifying HD pathogenesis.
  • To explore the potential mechanisms by which these genetic modifiers affect disease progression.

Main Methods:

  • Genotyping of candidate single nucleotide polymorphisms in a cohort of 3,314 HD subjects.
  • Genome-wide association analysis to confirm and identify modifier loci.
  • Genomic DNA capture and sequencing to localize functional variants within identified loci.
  • Expression Quantitative Trait Loci (eQTL) analysis to assess gene regulation.

Main Results:

  • Independent confirmation of modifier loci on chromosomes 8 and 15, and genome-wide significance for a locus on chromosome 3 at MLH1.
  • Identification of a functional variant in MLH1, present in ~32% of chromosomes, associated with a 0.7-year delay in HD motor onset per allele.
  • Localization of the functional variation to a 78kb region spanning MLH1 and LRRFIP2, including an isoleucine-valine missense variant in MLH1.
  • eQTL analysis suggested potential altered regulation of both MLH1 and LRRFIP2.

Conclusions:

  • Genetic modifiers significantly influence Huntington's disease onset age, with a variant near MLH1 providing a substantial protective effect.
  • The identified MLH1 variant and its associated region represent a promising target for understanding and potentially treating HD.
  • Further comprehensive genetic analyses in larger HD cohorts are warranted to uncover additional genetic modifiers.

Related Concept Videos